CSIMarket
 


Kinnate Biopharma Inc   (KNTE)
Other Ticker:  
 

Kinnate Biopharma Inc 's Tangible Leverage Ratio

KNTE's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


In Spite of the repayements of liabilities of -1.22%, in III Quarter 2023 ,Tangible Leverage Ratio deteriorated to 0.11, below the Kinnate Biopharma Inc 's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 68 other companies have achieved lower Tangible Leverage Ratio than Kinnate Biopharma Inc in the III Quarter 2023. While Tangible Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 93 to 205 .

Explain Tangible Leverage Ratio?
What is KNTE Market Share?
What are KNTE´s Total Liabilities?


KNTE Tangible Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity Change -30.57 % -27.8 % -24.7 % -30.05 % -27.18 %
Y / Y Total Liabilities Change -66 % -63.09 % -60 % -32.81 % -33.01 %
Tangible Leverage Ratio MRQ 0.11 0.09 0.09 0.25 0.22
KNTE's Total Ranking # 205 # 93 # 192 # 627 # 575
Seq. Tangible Equity Change -12.75 % -11.29 % -0.32 % -10.02 % -9.27 %
Seq. Total Liabilities Change -1.22 % -12.33 % -61.85 % 2.91 % 7.23 %



Tangible Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 69
Healthcare Sector # 111
Overall Market # 205


Tangible Leverage Ratio Statistics
High Average Low
0.26 0.18 0.09
(Dec 31 2021)   (Jun 30 2023)




Financial Statements
Kinnate Biopharma Inc 's Tangible Equity $ 172 Millions Visit KNTE's Balance sheet
Kinnate Biopharma Inc 's Total Liabilities $ 18 Millions Visit KNTE's Balance sheet
Source of KNTE's Sales Visit KNTE's Sales by Geography


Cumulative Kinnate Biopharma Inc 's Tangible Leverage Ratio

KNTE's Tangible Leverage Ratio for the trailling 12 Months

KNTE Tangible Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity TTM Growth -30.57 % -27.8 % -24.7 % -30.05 % -27.18 %
Y / Y Total Liabilities TTM Growth -66 % -63.09 % -60 % -32.81 % -33.01 %
Tangible Leverage Ratio TTM 0.14 0.17 0.19 0.2 0.21
Total Ranking TTM # 178 # 2 # 2 # 221 # 2
Seq. Tangible Equity TTM Growth -12.75 % -11.29 % -0.32 % -10.02 % -9.27 %
Seq. Total Liabilities TTM Growth -1.22 % -12.33 % -61.85 % 2.91 % 7.23 %


On the trailing twelve months basis Due to repayements of liabilities of -1.22% Kinnate Biopharma Inc decreased Tangible Leverage Ratio in the 12 months ending in III Quarter 2023 to 0.14, below the company's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 68, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Kinnate Biopharma Inc . While Tangible Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 2 to 178.

Explain Tangible Leverage Ratio?
What is KNTE Market Share?
What are KNTE´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 69
Healthcare Sector # 111
Within the Market # 178


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.26 0.18 0.09
(Dec 31 2021)   (Jun 30 2023)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Tangible Equity
Annovis Bio inc   0.29 $ 1.926  Millions$ 6.658  Millions
Homology Medicines Inc  0.29 $ 25.292  Millions$ 88.211  Millions
Corcept Therapeutics Inc  0.29 $ 132.343  Millions$ 461.679  Millions
Dermata Therapeutics Inc   0.29 $ 1.834  Millions$ 6.407  Millions
Inozyme Pharma Inc   0.28 $ 45.489  Millions$ 160.213  Millions
Allakos Inc   0.28 $ 62.452  Millions$ 221.043  Millions
Chemomab Therapeutics Ltd   0.28 $ 4.762  Millions$ 16.997  Millions
Lipella Pharmaceuticals Inc   0.28 $ 0.619  Millions$ 2.222  Millions
Siga Technologies Inc  0.28 $ 34.240  Millions$ 123.242  Millions
Sunshine Biopharma Inc   0.27 $ 5.687  Millions$ 20.747  Millions
Neurobo Pharmaceuticals Inc   0.27 $ 5.784  Millions$ 21.550  Millions
Imunon Inc   0.27 $ 4.846  Millions$ 18.072  Millions
Cara Therapeutics inc   0.26 $ 22.384  Millions$ 85.642  Millions
Lianbio  0.26 $ 60.564  Millions$ 236.112  Millions
Merus N v   0.25 $ 98.798  Millions$ 391.617  Millions
Regeneron Pharmaceuticals Inc   0.25 $ 5,996.300  Millions$ 23,887.200  Millions
Context Therapeutics Inc   0.25 $ 4.604  Millions$ 18.385  Millions
Bellerophon Therapeutics inc  0.25 $ 0.920  Millions$ 3.723  Millions
Savara Inc   0.24 $ 35.528  Millions$ 146.544  Millions
Assembly Biosciences Inc   0.24 $ 9.915  Millions$ 41.714  Millions
Erasca Inc   0.24 $ 80.431  Millions$ 338.975  Millions
Deciphera Pharmaceuticals Inc   0.23 $ 89.458  Millions$ 381.670  Millions
Calcimedica Inc   0.23 $ 2.826  Millions$ 12.159  Millions
Mei Pharma Inc   0.23 $ 18.835  Millions$ 81.361  Millions
Praxis Precision Medicines Inc   0.23 $ 19.969  Millions$ 86.756  Millions
Repare Therapeutics Inc   0.23 $ 53.039  Millions$ 233.368  Millions
Adial Pharmaceuticals Inc   0.23 $ 0.528  Millions$ 2.335  Millions
United Therapeutics Corporation  0.22 $ 1,270.900  Millions$ 5,667.700  Millions
Frequency Therapeutics Inc   0.22 $ 8.185  Millions$ 36.737  Millions
Ovid Therapeutics Inc   0.22 $ 22.512  Millions$ 101.292  Millions

Date modified: 2023-11-12T10:02:19+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com